Anti-Human IL‑23 p19 Recombinant Antibody (SAA0392) (HV466207)

Name: Anti-Human IL‑23 p19 Recombinant Antibody (SAA0392)
Brand: abinScience
SKU: HV466207
Price: 196 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

50ug
100ug

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HV466207
Reactividad de especies	Human
Aplicaciones	ELISA, FCM, WB
Especie huésped	Human
Clonalidad	Monoclonal
Isotipo	IgG4, kappa
ID de clon	SAA0392
Aplicaciones probadas	WB, FCM
Objetivo	IL-23 subunit alpha, IL-23-A, IL-23p19, IL23A, Interleukin-23 subunit alpha, Interleukin-23 subunit p19, SGRF
Nivel de endotoxinas	< 10 EU/mg
Pureza	>95% as determined by SDS-PAGE.
Purificación	Protein A/G purified from cell culture supernatant.
Número de acceso	Q9NPF7
Forma	Liquid
Buffer de almacenamiento	0.01M PBS pH 7.4. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Fondo	Interleukin-23 subunit alpha (IL23A) is a ~20 kDa protein. Associates with IL12B to form the pro-inflammatory cytokine IL-23 that plays different roles in innate and adaptive immunity. Released by antigen-presenting cells such as dendritic cells or macrophages, binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R to activate JAK2 and TYK2 which then phosphorylate the receptor to form a docking site leading to the phosphorylation of STAT3 and STAT4. This process leads to activation of several pathways including p38 MAPK or NF-kappa-B and promotes the production of pro-inflammatory cytokines such as interleukin-17A/IL17A. In turn, participates in the early and effective intracellular bacterial clearance. Promotes the expansion and survival of T-helper 17 cells, a CD4-positive helper T-cell subset that produces IL-17, as well as other IL-17-producing cells. IL23A is the therapeutic target of guselkumab (Tremfya). 1. Oppmann, B. et al. (2000) Immunity 13, 715-25. PMID: 11114383 2. Bloch, Y. et al. (2018) Immunity 48, 45-58.e6. PMID: 29287995 3. Sun, R. et al. (2020) Cellular and molecular gastroenterology and hepatology 10, 673-697. PMID: 32474165 4. Glassman, CR. et al. (2021) Cell 184, 983-999.e24. PMID: 33606986 5. Parham, C. et al. (2002) Journal of immunology (Baltimore, Md. : 1950) 168, 5699-708. PMID: 12023369 6. Wilson, NJ. et al. (2007) Nature immunology 8, 950-7. PMID: 17676044
Nota	For research use only.

Imágenes

Bioactivity

SEC-HPLC detection for Anti-Human IL23A Antibody (ABS0131).
Flow Cytometry

Flow-cytometry using anti-human IL23A antibody.IL23A Transfected CHO cells were stained with an irrelevant antibody (Blue Histogram) or an anti-human IL23A antibody monoclonal antibody (Catalog # HV466207 ,Green Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, bound antibody was detected using a FITC conjugated goat anti-human antibody (Catalog # HF690414) and cells analysed on a NovoCyte Flow Cytometer.
Western blot

Western blot analysis was performed using anti-IL23A monoclonal antibody at 1ug/mL on various samples.
Lane 1: recombinant human IL23A (Catalog No: HV466011)
Lane 2: negative control